tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mathew Blackman, 39 are a HOLD (41.49%), 55 are a BUY (58.51%).
Analyst Mathew Blackman works at STIFEL with a stock forecast success ratio of 59.2% fulfilled within 131.63 days on average.
Mathew Blackman’s has documented 184 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on GMED, Globus Medical at 21-Feb-2024.
Analyst best performing recommendations are on ELGX (ENDOLOGIX).
The best stock recommendation documented was for DXCM (DEXCOM) at 4/29/2020. The price target of $96.25 was fulfilled within 8 days with a profit of $9.88 (11.44%) receiving and performance score of 14.3.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
13
$3.22 (32.92%)
13
1 months 22 days ago
0/5 (0%)
$2.48 (23.57%)
Buy
13
$3.22 (32.92%)
9
1 months 29 days ago
2/8 (25%)
$2.73 (26.58%)
91
Buy
13
$3.22 (32.92%)
11
1 months 29 days ago
3/12 (25%)
$2.73 (26.58%)
98
Hold
8
$-1.78 (-18.20%)
14
5 months 18 days ago
6/13 (46.15%)
$1.5 (23.08%)
50
Buy
14
$4.22 (43.15%)
17
5 months 18 days ago
1/10 (10%)
$7.5 (115.38%)
113
Which stock is Mathew Blackman is most bullish on?
Which stock is Mathew Blackman is most reserved on?
What Year was the first public recommendation made by Mathew Blackman?
